Author:
Han Sola,Sohn Ted J.,Ng Boon Peng,Park Chanhyun
Abstract
AbstractCardiovascular disease (CVD) in cancer patients can affect the risk of unplanned readmissions, which have been reported to be costly and associated with worse mortality and prognosis. We aimed to demonstrate the feasibility of using machine learning techniques in predicting the risk of unplanned 180-day readmission attributable to CVD among hospitalized cancer patients using the 2017–2018 Nationwide Readmissions Database. We included hospitalized cancer patients, and the outcome was unplanned hospital readmission due to any CVD within 180 days after discharge. CVD included atrial fibrillation, coronary artery disease, heart failure, stroke, peripheral artery disease, cardiomegaly, and cardiomyopathy. Decision tree (DT), random forest, extreme gradient boost (XGBoost), and AdaBoost were implemented. Accuracy, precision, recall, F2 score, and receiver operating characteristic curve (AUC) were used to assess the model’s performance. Among 358,629 hospitalized patients with cancer, 5.86% (n = 21,021) experienced unplanned readmission due to any CVD. The three ensemble algorithms outperformed the DT, with the XGBoost displaying the best performance. We found length of stay, age, and cancer surgery were important predictors of CVD-related unplanned hospitalization in cancer patients. Machine learning models can predict the risk of unplanned readmission due to CVD among hospitalized cancer patients.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Chen, H. et al. Artificial intelligence applications in cardio-oncology: Leveraging high dimensional cardiovascular data. Front. Cardiovasc. Med. 9, 941148 (2022).
2. Koene, R. J., Prizment, A. E., Blaes, A. & Konety, S. H. Shared risk factors in cardiovascular disease and cancer. Circulation 133, 1104–1114 (2016).
3. Paterson, D. I. et al. Incident cardiovascular disease among adults with cancer: A population-based cohort study. J. Am. Coll. Cardiol. CardioOnc. 4, 85–94 (2022).
4. Ohtsu, H., Shimomura, A. & Sase, K. Real-world evidence in cardio-oncology: What is it and what can it tell us?. Cardio Oncol. 4, 95–97 (2022).
5. Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171–190 (2020).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献